| Cat. No. |
Product Name |
Information |
| PC-70061 |
ABT-724
Dopamine D4 agonist
|
ABT-724 is a potent, selective dopamine D4 receptor agonist that activates human dopamine D4 receptors with EC50 of 12.4 nM, with no effect on dopamine D1, D2, D3, or D5 receptors. |
| PC-70058 |
PD128907 hydrochloride
D3R agonist
|
PD128907 hydrochloride is a potent, selective and orally active agonist of dopamine D3 receptor (D3R) with Ki of 20 nM. |
| PC-70057 |
PF-219061
D3R agonist
|
PF-219061 (PF 219061, PF219061) is a potent, selective agonist of dopamine D3 receptor with EC50 of 8 nM. |
| PC-42584 |
SKF-82958 hydrobromide
Dopamine D1 agonist, ERα agonist
|
SKF-82958 hydrobromide is a potent, full dopamine D1 agonist, produces characteristic anorectic effects, hyperactivity and self-administration in animals. |
| PC-42583 |
SKF 82958
Dopamine D1 agonist, ERα agonist
|
SKF 82958 is a potent, full dopamine D1 agonist, produces characteristic anorectic effects, hyperactivity and self-administration in animals. |
| PC-45204 |
Metoclopramide
D2R antagonist
|
Metoclopramide is apotent dopamine D2 receptor antagonist with Ki of 28 nM. |
| PC-42716 |
SB-277011
D3R antagonist
|
SB-277011 (SB277011A) is a potent and selective dopamine D3 receptor antagonist with pKi of 8.0. |
| PC-25355 |
D-583
D2/D3 agonist
|
D-583 is a potent hybrid D2/D3 agonist and iron (II)-specific chelator with EC50 of 3.14 nM (Emax=63%) and 0.62 nM (Emax=68%) for D2 and D3 receptors respectively, exhibits anti-ferroptotic activity. |
| PC-25209 |
YQA14
D3R antagonist
|
YQA14 is a potent, selective D3 dopamine receptor (D3R) antagonist with Ki of 0.68 nM, shows no affinity for D2R. |
| PC-25208 |
SR 21502
D3R antagonist
|
SR 21502 is a potent, selective D3 dopamine receptor (D3R) antagonist with Ki of 4.2 nM, >120-fold binding selectivity over D2 receptor. |
| PC-25085 |
Raxlaprazine etomoxil
D3/D2 receptor modulator
|
Raxlaprazine etomoxil is a potent, selective dopamine D3/D2 receptor modulator. |
| PC-24638 |
Metopimazine
D2R antagonist
|
Metopimazine is a selective, peripherally restricted dopamine D2 receptor (D2R) antagonist, has potential for the symptomatic treatment of nausea and vomiting and chemotherapy-induced nausea and vomiting. |
